ProCE Banner Activity

Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD

Conference Coverage
Podcast Episodes

Listen as Marlyn J. Mayo, MD, discusses exciting new data from AASLD 2023 for people with PBC, including a late-breaking study of a dual PPAR agonist, biochemical response rates in people treated with an FXR agonist with or without a fibrate as second-line therapy, and evaluation of hyperlipidemia, atherosclerosis, and hepatic steatosis in people with PBC.

Released: December 06, 2023

Share

Faculty

Marlyn J. Mayo

Marlyn J. Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from CymaBay Therapeutics.

CymaBay Therapeutics

Disclosure

Primary Author

Marlyn J. Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Marlyn J. Mayo, MD: consultant/advisor/speaker: Cymabay, GlaxoSmithKline, Intra Sana, Mallinckrodt, Mirum; researcher: Cymabay, Genfit, GlaxoSmithKline, Intercept, Mirum, Target RWE.